Furthermore, small molecule c-MET inhibitors, including INC280, should be tested in combination with existing therapies in models of ovarian cancer post-debulking surgery, to address their usefulness in preventing survival, adhesion, and migration of cells remaining within the ascites fluid, and potentially preventing growth of micro-metastases. This evidence concerns the gene MET and ovarian cancer.